Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of oral ABL001 alone and with tyrosine kinase inhibitors in CML or Philadelphia chromosome-positive acute lymphoblastic leukemia
NL-OMON55523Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tovecimig in chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (6 arms), sponsored by Novartis. Primary endpoint: Number of dose-limiting toxicities. Started Nov 2015; status: active, not recruiting.
02
Drugs
tovecimig
03
Conditions
chronic myelogenous leukemia (CML)Philadelphia-chromosome positive acute lymphoblastic leukemia
Beyond the preview
Go deeper on NL-OMON55523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55523.